Narrative review: The emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

Annals of Internal Medicine

Volumn 150, Issue 11, 2009, Pages 776-783

  Sowers, James R ^b   Whaley Connell, Adam ^b   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTOKINE; ALDOSTERONE; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MINERALOCORTICOID RECEPTOR; SPIRONOLACTONE; ALDOSTERONE ANTAGONIST;

ADIPOSE TISSUE; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL FUNCTION; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CYTOKINE PRODUCTION; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCOSE TOLERANCE; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; HEART INFARCTION; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY INJURY; LIVER CIRRHOSIS; METABOLIC SYNDROME X; OBESITY; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TISSUE STRUCTURE; VASCULAR ENDOTHELIUM; VASODILATATION; BLOOD; KIDNEY DISEASE; PATHOPHYSIOLOGY; PHYSIOLOGY;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASES; METABOLIC SYNDROME X; RENIN-ANGIOTENSIN SYSTEM;

EID: 66549130863     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-150-11-200906020-00005     Document Type: Review

References (56)

1. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation. 2004;110:1245-1250 [PMID: 15326067] (Pubitemid 39202340)
2. Manrique C, Lastra G, Whaley-Connell A, Sowers JR. Hypertension and the cardiometabolic syndrome. J Clin Hypertens (Greenwich). 2005;7:471-476 [PMID: 16103758]
3. Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature. 2006;444:875-880 [PMID: 17167476] (Pubitemid 46028447)
4. Sowers JR. Metabolic risk factors and renal disease. Kidney Int. 2007;71:719-720 [PMID: 17429418] (Pubitemid 46624014)
5. Cooper SA, Whaley-Connell A, Habibi J, Wei Y, Lastra G, Manrique C, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009-23. [PMID: 17586614] (Pubitemid 47605846)
6. Epstein M. Aldosterone blockade: an emerging strategy for abrogating progressive renal disease. Am J Med. 2006;119:912-919 [PMID: 17071154] (Pubitemid 44634312)
7. Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Schindler O, et al. [Constitution of aldosterone, a new mineralocorticoid.]. Experientia. 1954;10:132-133 [PMID: 13161890]
8. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88:2364-2372 [PMID: 12788829] (Pubitemid 36724399)
9. Brown NJ. Aldosterone and vascular inflammation. Hypertension. 2008;51:161-167 [PMID: 18172061]
10. Wehling M, Christ M, Theisen K. Membrane receptors for aldosterone: a novel pathway for mineralocorticoid action. Am J Physiol. 1992;263:E974-9. [PMID: 1443130]
11. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318 [PMID: 16432039] (Pubitemid 43740260)
12. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650-656 [PMID: 2949071] (Pubitemid 17018455)
13. Epstein M, Williams GH, Weinberger M, Lewin A, Krause S, Mukherjee R, et al. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2006;1:940-951 [PMID: 17699311]
14. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717 [PMID: 10471456]
15. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321 [PMID: 12668699]
16. Goodfriend TL. Treating resistant hypertension with a neglected old drug [Editorial]. Hypertension. 2007;49:763-764 [PMID: 17309945]
17. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, Pimenta E, Aban I, Oparil S, et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168:1159-1164 [PMID: 18541823]
18. Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Aban I, Oparil S, et al. Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension. 2008;51:339-344 [PMID: 18086955]
19. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, et al; American Heart Association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008;117:e510-26. [PMID: 18574054]
20. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis. 2001;37:699-705. [PMID: 11273868] (Pubitemid 32268029)
21. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension. 2002;40:892-896 [PMID: 12468575] (Pubitemid 35434912)
22. Strauch B, Zelinka T, Hampf M, Bernhardt R, Widimsky J Jr. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17:349-352 [PMID: 12756408] (Pubitemid 36625965)
23. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens. 2004;22:2217-2226 [PMID: 15480108] (Pubitemid 39463817)
24. Kidambi S, Kotchen JM, Grim CE, Raff H, Mao J, Singh RJ, et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension. 2007;49:704-711 [PMID: 17159085] (Pubitemid 46263216)
25. Fletcher EC, Orolinova N, Bader M. Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol. 2002;92:627-633 [PMID: 11796674] (Pubitemid 34671030)
26. Ehrhart-Bornstein M, Lamounier-Zepter V, Schraven A, Langenbach J, Willenberg HS, Barthel A, et al. Human adipocytes secrete mineralocorticoid- releasing factors. Proc Natl Acad Sci U S A. 2003;100:14211-14216 [PMID: 14614137] (Pubitemid 37499216)
27. Freel EM, Ingram M, Friel EC, Fraser R, Brown M, Samani NJ, et al. Phenotypic consequences of variation across the aldosterone synthase and 11-beta hydroxylase locus in a hypertensive cohort: data from the MRC BRIGHT Study. Clin Endocrinol (Oxf). 2007;67:832-838 [PMID: 17651452] (Pubitemid 350135124)
28. Stowasser M, Gordon RD. Aldosterone excess, hypertension, and chromosome 7p22: evidence continues to mount [Editorial]. Hypertension. 2007;49:761-762 [PMID: 17339541]
29. Makhanova N, Hagaman J, Kim HS, Smithies O. Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension. 2008;51:134-140 [PMID: 18039983] (Pubitemid 350307115)
30. Lastra G, Whaley-Connell A, Manrique C, Habibi J, Gutweiler AA, Appesh L, et al. Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab. 2008;295:E110-6. [PMID: 18445755]
31. Liu SL, Schmuck S, Chorazcyzewski JZ, Gros R, Feldman RD. Aldosterone regulates vascular reactivity: short-term effects mediated by phosphatidylinositol 3-kinase-dependent nitric oxide synthase activation. Circulation. 2003;108:2400-2406 [PMID: 14557368] (Pubitemid 37413549)
32. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, et al. Aldosterone activates vascular p38MAP kinase and NADPH oxidase via c-Src. Hypertension. 2005;45:773-779 [PMID: 15699470] (Pubitemid 40418380)
33. Min LJ, Mogi M, Iwanami J, Li JM, Sakata A, Fujita T, et al. Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence. Cardiovasc Res. 2007;76:506-516 [PMID: 17706954] (Pubitemid 350007454)
34. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. N Engl J Med. 1965;273:1135-1143 [PMID: 5841677]
35. Bochud M, Nussberger J, Bovet P, Maillard MR, Elston RC, Paccaud F, et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension. 2006;48:239-245 [PMID: 16785327] (Pubitemid 44309818)
36. Fallo F, Veglio F, Bertello C, Sonino N, Della Mea P, Ermani M, et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab. 2006;91:454-459 [PMID: 16291704] (Pubitemid 43236909)
37. Giacchetti G, Ronconi V, Turchi F, Agostinelli L, Mantero F, Rilli S, et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens. 2007;25:177-186 [PMID: 17143190] (Pubitemid 44885680)
38. Catena C, Lapenna R, Baroselli S, Nadalini E, Colussi G, Novello M, et al. Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab. 2006;91:3457-3463 [PMID: 16822818] (Pubitemid 44402119)
39. Ehrhart-Bornstein M, Arakelyan K, Krug AW, Scherbaum WA, Bornstein SR. Fat cells may be the obesity-hypertension link: human adipogenic factors stimulate aldosterone secretion from adrenocortical cells. Endocr Res. 2004;30:865-870 [PMID: 15666838] (Pubitemid 40070185)
40. Rondinone CM, Rodbard D, Baker ME. Aldosterone stimulated differentiation of mouse 3T3-L1 cells into adipocytes. Endocrinology. 1993;132:2421-2426 [PMID: 8504747] (Pubitemid 23156890)
41. Caprio M, Fève B, Claës A, Viengchareun S, Lombès M, Zennaro MC. Pivotal role of the mineralocorticoid receptor in corticosteroid-induced adipogenesis. FASEB J. 2007;21:2185-2194 [PMID: 17384139]
42. Guo C, Ricchiuti V, Lian BQ, Yao TM, Coutinho P, Romero JR, et al. Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation. 2008;117:2253-2261 [PMID: 18427128]
43. Lamounier-Zepter V, Ehrhart-Bornstein M. Fat tissue metabolism and adrenal steroid secretion. Curr Hypertens Rep. 2006;8:30-34 [PMID: 16600157]
44. Goodfriend TL, Ball DL, Egan BM, Campbell WB, Nithipatikom K. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension. 2004;43:358-363 [PMID: 14718355] (Pubitemid 38174139)
45. Fallo F, Della Mea P, Sonino N, Bertello C, Ermani M, Vettor R, et al. Adiponectin and insulin sensitivity in primary aldosteronism. Am J Hypertens. 2007;20:855-861 [PMID: 17679033] (Pubitemid 47176347)
46. Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med. 1981;304:930-933 [PMID: 7010165] (Pubitemid 11101080)
47. Dall'Asta C, Vedani P, Manunta P, Pizzocri P, Marchi M, Paganelli M, et al. Effect of weight loss through laparoscopic gastric banding on blood pressure, plasma renin activity and aldosterone levels in morbid obesity. Nutr Metab Cardiovasc Dis. 2009;19:110-114 [PMID: 18718746]
48. Hitomi H, Kiyomoto H, Nishiyama A, Hara T, Moriwaki K, Kaifu K, et al. Aldosterone suppresses insulin signaling via the downregulation of insulin receptor substrate-1 in vascular smooth muscle cells. Hypertension. 2007;50:750-755 [PMID: 17646573] (Pubitemid 47442741)
49. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, et al. A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens. 2007;25:2125-2130 [PMID: 17885557] (Pubitemid 47476311)
50. Hayden MR, Sowers JR. Pancreatic renin-angiotensin-aldosterone system in the cardiometabolic syndrome and type 2 diabetes mellitus [Editorial]. J Cardiometab Syndr. 2008;3:129-131 [PMID: 18983326]
51. Wei Y, Whaley-Connell AT, Habibi J, Rehmer J, Rehmer N, Patel K, et al. Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation. Hypertension. 2009;53:158-165 [PMID: 19114643]
52. Stas S, Whaley-Connell A, Habibi J, Appesh L, Hayden MR, Karuparthi PR, et al. Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology. 2007;148:3773-3780 [PMID: 17494996]
53. Kim JA, Wei Y, Sowers JR. Role of mitochondrial dysfunction in insulin resistance. Circ Res. 2008;102:401-414 [PMID: 18309108]
54. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446 [PMID: 17082236] (Pubitemid 44865286)
55. Bomback AS, Klemmer PJ. Renal injury in extreme obesity: the important role of aldosterone [Letter]. Kidney Int. 2008;74:1216; author reply 1216-1217 [PMID: 18854852]
56. Whaley-Connell A, Habibi J, Wei Y, Gutweiler A, Jellison J, Wiedmeyer CE, et al. Mineralocorticoid receptor antagonism attenuates kidney renin-angiotensin-aldosterone system mediated filtration barrier remodeling in the transgenic ren2 rat. Am J Physiol Renal Physiol. 2009 [in press].